X0206 3 2020-10-15 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001788542 Mottiwala Aziz C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 0 1 0 0 Chief Commercial Officer Common Stock 53853 D Employee Stock Option (right to buy) 0.45 2028-09-13 Common Stock 3365 D Employee Stock Option (right to buy) 10.99 2030-09-24 Common Stock 19339 D Employee Stock Option (right to buy) 10.99 2030-09-24 Common Stock 50935 D The shares of common stock are subject to repurchase by the Issuer if the Reporting Person ceases to provide services to the Issuer prior to the vesting of the shares. The Issuer's right of repurchase lapses with respect to (i) 26,197 shares on August 17, 2021, (ii) 2,183 shares monthly for 12 months beginning on September 17, 2021, and (iii) 1,460 shares on September 17, 2022. Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter. Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020. Option granted under the Plan. The option shares vest and become exercisable as follows: (i) 724 shares vest and become exercisable on September 17, 2022; (ii) 2,183 shares vest and become exercisable monthly for the following 22 months after September 17, 2022; and (iii) 2,185 shares vest and become exercisable on August 17, 2024. Exhibit 24 - Power of Attorney /s/ Leo Greenstein, attorney-in-fact 2020-10-15